TABLE 1.
Patient characteristics
| Overall (n, %) | Multiple myeloma (n, %) | Chronic lymphocytic leukemia (n, %) | |
|---|---|---|---|
| Patients (n) | 122 | 60 | 62 |
| Gender | |||
| Female | 57 (47%) | 30 (50%) | 27 (44%) |
| Male | 65 (53%) | 30 (50%) | 35 (56%) |
| Median age (range), y | 64 (35‐81) | 64 (35‐81) | 64 (43‐81) |
| mRNA vaccine | |||
| BNT162b2 | 114 (93%) | 56 (93%) | 58 (94%) |
| mRNA‐1273 | 8 (7%) | 4 (7%) | 4 (6%) |
| ISS stage system for MM | |||
| ISS I | 30 (50%) | ||
| ISS II | 16 (27%) | ||
| ISS III | 8 (13%) | ||
| No data | 8 (13%) | ||
| Binet staging system for CLL | |||
| Binet A | 22 (35%) | ||
| Binet B | 26 (42%) | ||
| Binet C | 13 (21%) | ||
| No data | 1 (2%) | ||
| Disease status | |||
| Untreated | 12 (10%) | 2 (3%) | 10 (16%) |
| In treatment | 72 (59%) | 39 (65%) | 33 (55%) |
| In remission | 25 (20%) | 9 (15%) | 16 (26%) |
| No data | 13 (11%) | 10 (17%) | 3 (5%) |
| Steroids | 28 (23%) | 25 (42%) | 3 (5%) |
| Antibiotics | 12 (10%) | 4 (7%) | 8 (13%) |
| NSAID | 8 (7%) | 6 (10%) | 2 (3%) |
| Frequent infections | 15 (12%) | 5 (8%) | 10 (16%) |
| Anti‐SARS‐CoV‐2 antibodies at baseline | 35 (29%) | 22 (37%) | 13 (21%) |
| HLA‐A*02 positivity | 42 (34%) | 17 (28%) | 25 (40%) |
Abbreviations: ISS, International Staging System; NSAID, nonsteroidal antiinflammatory drugs.